


Volume 43 • Supplement 1 • August 2000



**Abstracts of the 36th Annual Meeting of the EASD  
Jerusalem, Israel, 17-21 September 2000**

Minutes of the 36th General Assembly  
of the European Association for the Study of Diabetes,  
Brussels, Belgium, 1 October 1999 • I

Agenda for the 36th General Assembly  
of the European Association for the Study of Diabetes,  
Jerusalem, Israel, 20 September 2000 • V

Abstracts A 1

Author Index A 295

Organisation Section A 317

The Abstract Volume of the 36th Annual Meeting of the Association is supported by an  
educational grant of GlaxoWellcome

Approved in Great Britain, India, Australia and elsewhere  
© 2000 by Blackwell Science Ltd  
Printed on acid-free paper



**Springer**

## **FIVE-DAY DOSING OF SYNTHETIC EXENDIN-4 (AC2993) IN PEOPLE WITH TYPE 2 DIABETES REDUCES POST-PRANDIAL GLUCOSE, GLUCAGON AND TRIGLYCERIDE CONCENTRATIONS**

**O. Kottmann, A. Gottlieb, E. Gahner, M. Flanagan**

**San Diego, CA, USA**

**Background and Aim:** We evaluated the safety, tolerability, and efficacy of synthetic exendin-4 (AC2993) in 24 patients with type 2 diabetes (DM2) previously treated with diet, oral hypoglycemic agents (OHA), or insulin in a single-blind, placebo controlled, two-period crossover study.

**Materials and Methods:** 14 days prior to randomization, OHA therapy was stopped and subjects using insulin were stabilized on a single is NPH injection. Each patient was randomized to receive subcutaneous (SC) injections BID (7:00 and 17:00 hrs) of placebo (PBO) or 0.1 µg/kg AC2993 for 5 days. Following a 2-3 day washout, subjects were crossed over to the other treatment. Plasma glucose (PG), glucagon and serum triglyceride (TG) concentrations were assessed fasting and in response to a 7 Kcal/kg Sustacal® meal administered at the time of the morning AC2993/PBO injection on days 1 and 5.

**Results:** Reported adverse events, ECG, physical exam, and safety lab monitoring revealed no safety issues. Nausea and vomiting were the most frequent adverse events; however all were reported as mild in intensity. Postprandial circulating PG, glucagon, and TGs were significantly reduced following AC2993 compared to PBO on both days 1 and 5. On day 5, the 3-hour time-weighted mean  $\pm$  SE change in PG from baseline fasting values was  $-7.7 \pm 5.1$  mg/dL for AC2993 compared to  $67.2 \pm 7.9$  mg/dL for PBO, ( $P < 0.0001$ ). The 3-hr postprandial plasma glucagon AUC was reduced by 23% compared to PBO ( $P = 0.0123$ ) and the rise in postprandial TGs was suppressed as evidenced by a 24% reduction in peak postprandial TG concentrations compared to PBO ( $P = 0.0001$ ).

**Conclusions:** 0.1 µg/kg AC2993 BID for 5 days in patients spanning the spectrum of type 2 diabetes identified no safety issues, reduced circulating postprandial plasma glucose, glucagon and triglyceride concentrations.

**Clinical diabetes**